Taizhou Hanzhong biomedical co. LTD Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03704246
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Taizhou Hanzhong biomedical co. LTD